Artiva Biotherapeutics (ARTV) EBITDA (2023 - 2026)

Artiva Biotherapeutics (ARTV) has 4 years of EBITDA data on file, last reported at -$24.4 million in Q1 2026.

• On a quarterly basis, EBITDA fell 10.19% year-over-year to -$24.4 million in Q1 2026; TTM through Mar 2026 was -$92.1 million, a 22.82% decrease from a year earlier, with the FY2025 full-year figure at -$89.8 million, down 33.48% from the prior year.
• EBITDA for Q1 2026 stood at -$24.4 million, down from -$21.9 million in the prior quarter.
• Over the last five years, EBITDA for ARTV reached as high as $10.8 million in Q3 2023 and fell as low as -$24.4 million in Q1 2026.
• Historically, EBITDA has averaged -$16.2 million across 4 years, with a median of -$18.3 million in 2024.
• Across the five-year window, EBITDA plunged 269.6% in 2024 and decreased 10.19% in 2026, its largest moves.
• Year by year, EBITDA stood at -$12.0 million in 2023, then sank by 52.61% to -$18.3 million in 2024, then declined by 20.06% to -$21.9 million in 2025, then fell by 11.39% to -$24.4 million in 2026.
• Per Business Quant data, the three most recent EBITDA figures were -$24.4 million in Q1 2026, -$21.9 million in Q4 2025, and -$22.9 million in Q3 2025.